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Zusammenfassung
Hintergrund: Die neuen Richtlinien zur Diagnose einer Latenten Tuber-
kuloseInfektion(LTBI)beiBeschäftigtenimGesundheitswesenempfeh-
Alameda Professor Hernâni
Monteiro, Porto, Portugal
len den Interferon-gamma Release Assays (IGRA) als Diagnoseinstru-
ment. Trotz wachsender Erfahrung mit dem Test liegen bislang nur
wenige Daten zum Seriellen Testen vor. Dies gilt vor allem für Länder
mit niedriger LTBI- Prävalenz. Bei wiederholten Tests ist bislang unklar,
ab wann von wahren „Konversionen und Reversionen“ auszugehen ist,
wie diese interpretiert werden sollen und wann eine Chemoprävention
indiziert ist. Wir haben in unserer Studie Konversions- und Reversions-
raten bei Beschäftigten im Gesundheitsdienst analysiert.
Methode: Insgesamt wurden 287 Beschäftigte im Gesundheitswesen,
die routinemäßig arbeitsmedizinisch auf TB untersucht wurden, in die
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Research Article OPEN ACCESSStudieeingeschlossenundzuzweiZeitpunktenmitdemQuantiFERON-
TB Gold In Tube (QFT) untersucht. Vier unterschiedliche Definitionen
fürKonversionenundReversionenwurdenanalysiert.Zusätzlichwurde
die Verwendung einer Grauzone um den Grenzwert (0,35 IU/ml) von
0,2–0,7 IU/ml untersucht.
Ergebnisse: Bei 15% der Beschäftigten waren beide Testergebnisse
positiv. Die höchsten Konversion (6,1%) und Reversionsraten (32,6%)
wurden mit der am wenigsten stringenten Definition von negativ zu
positiv beobachtet. Die niedrigsten Raten (2,5%) fanden sich bei der
strengsten Definition mit einem Anstieg von ≥0,7 IU/ml über dem
Grenzwert von 0,35 IU/ml. Bei der Verwendung einer Grauzone von
0,2–0,7 IU/ml um den Grenzwert lagen die Konversionsrate bei 2,6%
und die Reversionsrate bei 15,4%. Bei einem positiven QFT-Test wurde
eine Röntgenuntersuchung zum Ausschluss einer aktiven Tuberkulose
(TB) durchgeführt. Keiner der Probanden hat bislang eine aktive TB
entwickelt.
Schlussfolgerung: Die Konversions- und Reversionsraten variieren in
Abhängigkeit der jeweiligen Definition. Unsere Daten bestätigen die
AnnahmeeinerGrauzonezwischen0,2und0,7IU/mlbeiwiederholten
RoutineuntersuchungenvonPersonenmiteinemerhöhtenLTBI-Risiko.
Dies sollte in einer größeren Studienpopulation evaluiert werden. Zur
ProgressionsrateeinespositivenQFTinNiedrig-Inzidenzländernliegen
wenige Daten vor. Deshalb sollten Personen, deren Testergebnisse in
dieseGrauzonefallenvorBeginneinerChemopräventionnochmalsmit
dem QFT untersucht werden.
Schlüsselwörter: Serielles Testen, Interferon-gamma Release Assay,
Latente Tuberkulose-Infektion, Beschäftigte im Gesundheitsdienst
Introduction
The increased risk of latent tuberculosis infection (LTBI)
and active TB as an occupational disease in healthcare
workers is well established [1]. Therefore, the screening
of healthcare workers (HCW) for LTBI and preventive
treatment are fundamental components of prevention
programmes [2]. Serial testing either after recent expos-
uretoaconfirmedTBsourcecase(contactinvestigation)
orwithinperiodicaloccupationalsafetyandhealth(OSH)
measures are required for surveillance and with regard
totherecognitionandcompensationofTBasanoccupa-
tional disease [3].
However, the conventional tuberculin skin test (TST) has
knownlimitationsinaccuracyandreliability.Furthermore,
interpretation of serial TST results is complicated by non-
specificvariationandbecauseofitsintradermalapplica-
tion, by potential boosting by precedent tests [4]. The in-
terferon-gamma (INF-γ) release assays (IGRAs) provide a
new tool for LTBI diagnosis and surveillance for new TB
infections [5]. The IGRAs allow ex-vivo testing and there-
fore are not prone to boosting. Furthermore, IGRAs are
highly specific, giving them advantages over the TST es-
pecially in Bacillus Calmette Guérin (BCG)-vaccinated
populations [6], [7]. Although IGRAs have been recom-
mendedforserialtestinginsomecountries[2],[8],there
is still uncertainty regarding the interpretation of serial
IGRA test results [5], [9]. A few studies suggest that con-
versions, reversions and non-specific variations occur
with the IGRA in serial testing just as they do in TST serial
testing [10], [11], [12], [13], [14]. So far there is no con-
sensus on how to define and interpret IGRA conversions
and reversions and deal with such results [5].
As with the TST, IGRA results are determined by several
factors such as precision of measurement technique, in-
trapersonal biological variation, new infection (conver-
sion),transientinfectionandtransitionofMycobacterium
tuberculosis (MTB) from replication to a dormant state
no longer stimulating cell-mediated immune response
(reversion). MTB cannot be directly observed in the body.
Its presence and replication activity can therefore only
be measured indirectly by antigen-specific response via
a TST or an IGRA [12].
Data on IGRA interpretation in serial testing is scarce.
Preliminary data showed that, similar to with a TST, a
simplisticdichotomousnegativetopositivedefinitionmay
not be appropriate. The few published studies are
hampered by small sample sizes and allow limited con-
clusions [5], [10], [13], [14], [15], [16]. Consequently,
different ‘uncertainty zones’ around the manufacturer's
predefined cut-points as well as definitions of ‘true’ con-
versions and reversions have been suggested [5]. Based
on Indian data, a person whose IFN-γ result increased
from <0.20 and exceeded 0.50 IU/ml on the repeat test
was considered to have a ‘true conversion’. Likewise, a
personwhoseIFN-γresultdecreasedfrom>0.50andfell
to <0.20 IU/ml was considered to have a ‘true reversion’
[5]. Based on South African data, it was suggested that
an increase in IFN-γ response from below 0.35 IU/ml to
above 0.70 IU/ml for the QFT assay could be used to
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rates were reported when the first QFT showed INF-γ
concentration of between 0.35 and 0.7 IU/ml [15].
In our prospective cohort study we analysed conversion
and reversion rates in serial testing of HCWs with QFT
depending on baseline concentration of INF-γ as well as
for different definitions of conversions and reversions.
AssumingthatasmallvariationinbaselineINF-γconcen-
tration does not result in high changes to conversion and
reversion rates, we attempted to derive an uncertainty
zone around the cut-off for the QFT to be used in serial
testing.
Materials and methods
Study design and subjects
Thepopulationofthisprospectivecohortstudycomprises
HCWs from 14 different hospitals in Germany, who par-
ticipated in annual or biennial routine TB screening from
January 2006 to October 2009, in accordance with the
German guidelines for occupational safety and health
(OSH) or TB contact investigations after exposure to cul-
ture- confirmed TB-source cases by occupational phys-
icians. We did not apply a recent TST, because in accord-
ance with the national guideline from 2007 the IGRA is
recommendedforthescreeningproceduresamongHCW.
All participants were evaluated at baseline using a
standardised interview and questionnaire and the QFT.
AllparticipantswithapositiveQFTatbaselineorshowing
a conversion were offered a clinical and radiological ex-
amination to rule out active TB. The subsequent offer of
preventive chemotherapy with Isoniazid for 9 months
according to the current national recommendations was
the responsibility of the respective occupational health
practitionerandthepractice-basedpulmonaryspecialist
[8]. No one of the study population with a positive QFT at
baselineacceptedchemotherapy.Thefollow-upincluded
a second QFT and a second standardised questionnaire.
FollowingCDCandnationalguidelines,HCWsininfection
and TB wards are considered to be at high risk, workers
withregularpatientcontactinotherwardsareconsidered
to be at medium risk and workers with no regular patient
contactornocontacttobiologicalmaterialareconsidered
tobeatlowrisk[2],[3].Uponcommencementofemploy-
ment, all workers are examined. HCWs considered high-
riskareevaluatedannually.Allothersareevaluatedevery
otheryearorafterknownexposuretopatientswithactive
TB.
Questionnaire items
Informationonthefollowingvariableswascollectedusing
a standardised questionnaire: age, gender, reason for
testing, occupational exposure to TB, time spent working
in healthcare sector, own and family history of TB, place
ofbirth,priorTSTresults,jobtitle,workplace,chestradio-
graph findings and BCG vaccination. BCG vaccination
historywasassessedthroughtheindividual’svaccination
record or scars.
Diagnostic methods
For the IGRA, the QuantiFERON-TB
® Gold In-Tube assay
(CellestisLimited,Carnegie,Australia)wasadministrated
following the manufacturer’s protocol. The test was con-
sidered positive if INF-γ was ≥0.35 IU/ml after correction
forthenegativecontrol.Concentrationsofabove10IU/ml
weresetat10IU/mlbecauseofimprecisionofmeasure-
ment at these high concentrations [5]. The mean period
betweenthetwotestswas12months(standarddeviation
4 months).
Definitionsofconversionsandreversions
One of our objectives was to assess whether variations
in definitions produce different rates of conversion and
reversion. Therefore, four different definitions for conver-
sion and reversion were applied: 1) transgression or re-
gressionbasedonthecut-offfrom0.35IU/ml;2)increase
from <0.2 to >0.7 IU/ml or decrease from >0.7 to <0.2
IU/ml; 3) transgression or regression above cut-off (0.35
IU/ml) plus change of ≥0.50 IU/ml; and 4) transgression
or regression above cut-off (0.35 IU/ml) plus change
≥0.70 IU/ml.
Uncertainty zone analyses
Previous studies had suggested the use of a grey zone
for QFT results. Harada et al. used a grey zone of 0.10 to
0.35IU/mlandexcludedresultsinthiszonefromconver-
sion rate calculations. Pai et al. [4] used an approach of
drawing a zone uncertainty of 0.20 to 0.50 IU/ml. We
exploredanalternativegreyzonefrom0.20to0.70IU/ml
and excluded all those who had at least one QFT within
this grey zone from calculation.
Statistical analysis
Baseline INF-γ concentration was categorised in small
increments in order to observe at which increment the
highestchangeinconversionandreversionratesoccurs.
A 95% confidence interval (CI) for proportions was calcu-
lated. If the 95% CI did not overlap, differences between
proportionswereconsideredtobestatisticallysignificant.
Chi-square tests were used for categorical data.
Thestudyprotocolwasapprovedbytheethicscommittee
of the Hamburg Medical Council. All participants gave
their written informed consent prior to their inclusion in
the study.
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Study population and baseline results
Twohundredandeighty-sevenHCWswithtwoconsecutive
QFT tests were enrolled in this study. No indeterminate
results were observed. The baseline characteristics of
the study cohort are shown in Table 1. 78% of the cohort
was female and the median age was 40 years. Nurses
and doctors made up 57.8% of the study population.
79.8%(n=229)ofthecohortshowedpersistentlynegative
QFT results over a mean period of 12 months (standard
deviation 4 months) and 10.1% (n=29) was persistently
positive in both tests (no table).
53.3% of the conversion occurred in nurses and 20% in
doctors (Table 2). 40% of participants with a conversion
workedonwardswithahighrisk,e.g.infection/admission
ward or pulmonology ward, while 26.6% worked in a
laboratory, in pathology or on a radiology department.
Incidence of QFT conversions and
reversions
The first and second QFT was positive in 15.0% of the
HCWs (Table 3). If a simple dichotomous approach
(negative to positive and vice versa) was chosen, a con-
version occurred in 6.1% of those negative in the first
QFT and a reversion occurred in 32.6% of those positive
inthefirstQFT.Reversionandconversionratesdepended
on the INF-γ concentration of the first QFT. Conversion
occurred in 4.5% of the 201 HCWs with an INF-γ concen-
tration at baseline below 0.1 IU/ml but in 26.7% of the
15 HCWs with an INF-γ concentration of 0.2 to <0.35
IU/ml.Inthe12HCWswithabaselineINF-γconcentration
of >1.0 to 3.0 IU/ml tree reversions (25.0%) occurred,
while in the 16 (11+5) HCWs with a baseline INF-γ con-
centration of ≥0.35 to <0.7 IU/ml approximately every
second HCW showed a reversion.
Thehighestconversionandreversionratesof6.1%(95%
CI 3.5 to 9.9) and 32.6% (95% CI 19.1 to 48.5) were ob-
served with the least stringent definition of negative to
positive.Themoststringentdefinitionofanincreasefrom
≥0.7 IU/ml above the cut-point produced the lowest
conversion rate of 2.5% (95% CI 0.9 to 5.3). Conversion
and reversion rates showed differences depending on
the definition used (Table 4). The 95% CI of these rates
overlapped, indicating no statistically significant differ-
ence. There was, however, an almost two-fold difference
betweenthemoststringentandleaststringentdefinitions
for QFT conversion.
Foralldefinitionsconversionrateswerelowerthanrever-
sion rates but the difference was statistically significant
only for the least stringent definition (1a+b, Table 4).
Table 1: Description of the study population
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Table 3: Results of second QFT depending on INF-γ concentration in first QFT
Uncertainty zone analysis results
Using a grey zone from 0.2 to 0.7 IU/ml and excluding all
those who have at least one QFT within this grey zone
fromcalculationgavelowconversion(2.6%)andreversion
rates (15.4%). Slightly higher rates were obtained when,
in addition to a positive to negative approach, a minimal
chanceof0.5IU/mlwasrequestedforconversion(4.5%)
and reversion (14.0%).
Clinical outcome at baseline and
follow-up
Active TB was ruled out by chest X-rays in all participants
withapositivebaselineQFTandthosewithaconversion.
None of the 287 participants have developed active TB
within the study period from January 2006 to October
2009 so far.
5/8 GMS Krankenhaushygiene Interdisziplinär 2010, Vol. 5(2), ISSN 1863-5245
Schablon et al.: Serial testing with an interferon-γ release assay ...Table 4: Number and rate of conversions and reversions depending on different definitions for ‘true’ conversions and ‘true’
reversions
Discussion
Thecell-basedIGRAshavefeaturesthatmakethemideal
for serial testing. However, data on IGRA interpretation
in serial testing is rare, especially for low-incidence
countries. Our study therefore provides useful data on
QFTperformanceamongHCWsinalow-incidencecountry.
Thedataconfirmsthefindingsofpreviousstudies,which
suggestthatasimplisticdichotomousnegativetopositive
definition of the IGRA may be misleading due to the high
number of spontaneous conversions and reversions.
Consequently,conversionsandreversionswerefrequent
when IFN-γ values were close to the cut-point. Therefore,
using an uncertainty zone around the cut-point could be
helpful in distinguishing between unimportant variation
and true conversion or reversion.
QFTconversionsandtheirinterpretation
Theobservedconversionrateinourstudywasthehighest
(6.1%) when the least stringent definition, i.e. transition
from negative to positive values, was used, compared to
the conversion rate from 2.5% when the most stringent
definition was used. Our observed conversion rates from
2.5% up to 6.1% depending on the definition used was
higher than the conversion rate of 1.8% as shown in the
Japanese HCW study from Yoshiyama and colleagues
[15]. In another study from an intermediate-incidence
country,whereonlyIGRA-negativesubjectswereretested,
the observed conversion rate was 4.9% [17]. In contrast
to our findings, a conversion rate from 11.6% and 24%
was reported for Indian HCWs [13].
The prognosis of IGRA conversions and the potential use
ofIGRAsasapredictivetestareimportantissues.Studies
on TB prediction by QFT show promising results in low-
incidence countries. So far no study is available that de-
scribes the association between changes in IGRA and
disease prediction [18]. Pai [19] stated that serial IGRA
testingcanrevealinterestingunderlyingphenotypesthat
have different histories and trajectories. Some subjects
convert from negative to positive and then revert again.
Some converted and remained converted, while others
stayed positive for a long time. However, no data exists
to link these trajectories of test results with disease pro-
gression.Itisinconceivablethatallsubjectswillhavethe
sameprognosis.Therefore,Paisuggestedthatthosewho
are persistently negative should have the best prognosis
compared to those who recently converted and stayed
positive.Nevertheless,withoutserialtestingtheunderly-
ingphenotypesarenotseparableandthiswillundermine
the predictive value of a single test result [19].
Until now only a few studies have demonstrated the
prognosis of a positive QFT. Diel et al. [18] determined
thepredictivevalueoftheIGRAfordevelopmentofactive
tuberculosis after recent infection. They found a progres-
sion rate of 14.6% within the QFT positive subjects who
had declined chemoprevention. All of these subjects had
highly positive QFT results of >10 IU/ml. These findings
led to the hypothesis that individuals with a strongly ele-
vated IFN-γ concentration are most likely to progress to
active TB. Consequently, a second cut-off, higher than
the diagnostic cut-off, could be used to identify the sub-
group that would benefit from preventive chemotherapy
[19].
IGRA reversions and their interpretation
InlinewithpreviousstudiesamongHCWs,wefoundmore
reversions (32%) than conversions (6.1%) with the least
stringent definition and 2.5% (conversions) and 14.0%
(reversions) with the stringent definition of an increase
from ≥0.7 IU/ml above the cut-point. In contrast to our
findings, in the recent study among Japanese HCWs the
conversion rate was much lower (1.8%), while the rate of
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eous reversions were rare (n=3) when the baseline IFN-
concentration was >1 IU/ml. No reversion was observed
when the baseline IFN-concentration was >3 IU/ml
In order to interpret and use the IGRAs in serial testing,
we need evidence on several questions about the repro-
ducibilityofT-cellresponseovertimeandwhatthreshold
should be used to define true reversion [9], [19]. Serial
testing studies demonstrated that IGRAs are highly dy-
namic tests and T-cell responses, especially weak re-
sponses tend to fluctuate over time [9]. In the Gambian
Studyamonghouseholdcontactsahighrateofreversion
was revealed within a time span of just three months
[10].
One important question is why IGRA reversions occur. As
reviewed recently, some reversions may reflect the
clearing of the TB infection, some may merely be due to
biologicalvariationsamongthepositiveIGRAs,andsome
maybeduetovariabilityinlaboratoryandtestprocedures
[9].Recently,Hilletal.suggestedthattheIGRAresponses
areinherentlytransientandmayrequirecontinuedexpos-
ure to a TB antigen to maintain high frequencies [10]. In
line with Nardell [20], they speculated that reversions
may simply reflect the life cycle of Mycobacterium tuber-
culosis,wheretheMycobacteriumentersadormantstate
inwhichitmaynotreliablysecreteantigenssuchasESAT-
6 and CFP-10. It is unclear whether an IGRA reversion
indicates clearance or resolution of the TB infection.
Further research is needed to elucidate the prognosis of
IGRA reversions.
Uncertainty zone analysis results
Only a limited number of recent studies focused on the
reproducibilityofT-cellresponseovertime(within-subject
variability) and uncertainty zones analyses in order to
improve the interpretation of the IGRA results in serial
testing [5], [16], [21], [22], [23]. Using the borderline
zone of 0.2 to 0.70 UI/ml in our study and excluding all
those who have at least one QFT within this grey zone
fromcalculationgavelowconversion(2.6%)andreversion
rates (15.4%). However, when using an uncertainty zone
of 0.2 to 0.7 IU/ml it should be kept in mind that a QFT
result around the cut-off (0.35 IU/ml) does not exclude
active TB. Therefore, using a borderline zone in serial
testingshouldalwaysbecarefullyinterpretedwithconsid-
erationofrelevantclinicalsymptoms[16].Thisisbecause
an uncertainty zone means that spontaneous, clinically
irrelevant transgressions above the cut-off are probably
predominant, but LTBI or even active TB cannot be ex-
cluded.
Despite our increasing knowledge, several key questions
about latent infection and reactivation of M. tuberculosis
remain unanswered. Particularly, it should be noted that
both the TST and the IGRA are designed to identify an
adaptive immune response against M. tuberculosis, but
not necessarily a latent infection. A positive result of
currentlyavailablediagnostictestsisprimarilyameasure
ofanimmunologicalresponsetostimulationbymycobac-
terialantigensthatshouldnot,therefore,beequatedwith
the presence of live M. tuberculosis in the human host.
The proportion of individuals who truly remain infected
with M. tuberculosis after IGRA conversion is unknown.
Itisalsouncertainhowlongadaptiveimmuneresponses
towards mycobacterial antigens persist in the absence
of live mycobacteria. For these reasons, according to the
recentlypublishedTBNETconsensusstatementregarding
latent TB, based on the informative data currently being
produced by IGRA and TST, the term “latent infection” at
bestimplicates“lastingtuberculosisimmuneresponses”
and does not necessarily identify a true latent infection
with viable microorganisms and the potential risk of de-
veloping active disease [24].
Conclusion
The rate of conversions seemed to vary depending on
thedefinitionsused.Inconclusion,ourdatasuggeststhe
use of an uncertainty zone between 0.2 and 0.7 IU/ml in
serial testing with the QFT. Therefore, using a borderline
zone in serial testing in HCW should always be carefully
interpreted with consideration of relevant clinical symp-
toms. Using a borderline zone is only recommended for
serialtestingamongadult,healthyandimmunocompetent
subjects in low incidence countries like HCW. The use of
an uncertainty zone is not valid and not recommended
for example in pre-treatment screening before anti-TNF-
alpha therapy, because of the higher risk for progression
from LTBI to active TB in immunocompromised persons.
Further research is needed to confirm this grey zone in
largerHCWstudies.Tothebestofourknowledge,disease
progression in QFT-positive persons is limited in low-inci-
dencecountrieswithlittleexperienceinchemoprevention.
Persons belonging to this zone should be retested imme-
diately before being offered preventive chemotherapy.
StudiesonthediseasepredictionofvariationsinQFTwill
answer some of these questions.
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